<DOC>
	<DOCNO>NCT00689299</DOCNO>
	<brief_summary>The purpose study identify effective dose allergen-specific immunotherapy cat hair ( Felis domesticus ) administer oral/sublingual route .</brief_summary>
	<brief_title>Phase 2 Study Adults Sensitized Cat</brief_title>
	<detailed_description>This phase 2 , randomize , double-blind , placebo-controlled , parallel group study conduct 3 center US ( NCT00689299 ) . Study drug sublingually dose daily 0.15 mL US standardize cat hair extract dose either undiluted , 1:10 dilution , placebo . Target dose obtain Day 3 dose titration escalate 1:100 1:10 dilution Day 1 Day 2 high dose group placebo 1:100 dilution low dose group . Treatment duration 20 week . Adult ( &gt; 18 year ) study subject positive history cat allergy without asthma , positive skin test cat allergen , absence immunotherapy prior 2 year , absence confound baseline condition . The primary outcome parameter average Total Symptom Score ( TSS ) 1-hour cat chamber exposure . TSS sum 7 item rat 0 - 3 ( none severe ) nasal symptom ( rhinorrhea , nasal congestion , nasal itching , sneeze ) non-nasal symptom ( eye watering , eye itching , itch palate/ ear/ throat ) .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Male female patient age 18 55 year ( inclusive ) . Written inform consent participate study . Documented allergy cat hair demonstrate positive epicutaneous skin test ( wheal &gt; 3 mm ) symptoms allergic rhinitis exposure cat . Female subject childbearing potential , define surgically sterile least 2 year postmenopausal , must agree use one follow form contraception screen 4 week followup period follow last dose clinical trial : hormonal begin &gt; 30 day prior screen , barrier , intrauterine device vasectomize partner ( 6 month minimum ) . No clinically significant abnormal finding physical examination , exception head , ears , eye , nose , throat ( HEENT ) finding consistent allergic rhinitis , medical history , clinical laboratory result screen would jeopardize safety subject impact validity study result . Previous allergen immunotherapy ( subcutaneous immunotherapy ( SCIT ) , oral immunotherapy , sublingual immunotherapy ( SLIT ) recombinant peptide ) cat within 24 month Screening Visit . History severe allergic reaction require medical intervention . Intolerance severe allergic reaction previous immunotherapy ( SCIT , oral immunotherapy , SLIT , recombinant peptide ) . Allergy nonantigen ingredient study drug formulation , include , limited : Food , Drug Cosmetic Act ( FD &amp; C ) Yellow # 5 , Red # 40 Blue # 1 ; sodium chloride ; sodium bicarbonate ; glycerine . History asthma require daily medication . Subjects receive antiIgE monoclonal antibody . Congenital immune deficiency acquire immune suppression . Causes acquire immune suppression may include , limited , systemic illness malignancy infection , use medication corticosteroid chemotherapeutic agent , radiation therapy . History organ transplant , hematologic malignancy , autoimmune disease , myocardial infarction , congestive heart failure . History clinically significant gastrointestinal , renal , hepatic , neurologic , hematologic , endocrine , oncologic , pulmonary , psychiatric , cardiovascular disease , condition , opinion Investigator , would jeopardize safety subject impact validity study result . Inability unwillingness stop use drug may inhibit whealandflare reaction rhinitic response prior study duration dose clinical trial material ( CTM ) , exception protocolspecified rescue medication provide study site use Study Day 0 . This include , limited : Decongestants 3 day prior Study Day 0 H1 antagonist ( antihistamine ) ( oral , nasal ocular ) 7 day prior Study Day 0 Topical intranasal corticosteroid 14 day prior Study Day 0 Cromolyn nedocromil 14 day prior Study Day 0 Systemic corticosteroid 28 day prior Study Day 0 Tricyclic antidepressant 28 day prior Study Day 0 Leukotriene modifier 7 day prior study Day 0 Inability unwillingness stop use drug may inhibit ability treat severe allergic adverse event . This include , limited : beta blocker atenolol ( Tenormin® ) , metoprolol ( Lopressor® , ToprolXL® ) propranolol ( Inderal® , Inderal LA® ) 14 day prior Study Day 0 duration study . Female subject try conceive , pregnant , lactate . Positive serum pregnancy test screen positive human chorionic gonadotropin ( HCG ) urine test Study Day 0 prior administration study drug woman childbearing potential . Positive blood screen human immunodeficiency virus ( HIV ) , Hepatitis B surface antigen ( HbSAg ) , Hepatitis C. Forced Expiratory Volume 1 second ( FEV1 ) &lt; 70 % predict value . History alcohol drug abuse within year prior Screening Visit , current evidence substance dependence abuse . Participation clinical trial receipt nonFDA approve therapy within 30 day prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Sublingual Immunotherapy ( SLIT )</keyword>
	<keyword>Non-seasonal allergic rhinitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Cat</keyword>
	<keyword>Perennial allergy</keyword>
	<keyword>Non-seasonal allergy</keyword>
</DOC>